Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities

Leukemia

Volumn 10, Issue 7, 1996, Pages 1127-1133

  Patmasiriwat, P ^a   Fraizer, G C ^a   Claxton, D ^a   Kantarjian, H ^a   Saunders, G F ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Factors; GATA 1; Transcription; Tumor suppressor; WT1

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CELL; CANCER CLASSIFICATION; CHROMOSOME 16Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030035437     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE. Isolation and characterization of a zinc-finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 1990; 60: 509-520.
2. Riccardi VM, Sujansky E, Smith AC, Francke U. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics 1978; 61: 604-610.
3. Kaneko Y, Eques J, Rowley J. Interstitial deletion of short arm of chromosome 11 limited to Wilms tumor cells in a patient without aniridia. Cancer Res 1981; 42: 4577-4578.
4. Young JC, Miller RW. Incidence of malignant tumors in US children. J Pediatr 1975; 86: 254-258.
5. Pritchard-Jones K, Renshaw J, King-Underwood L. The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. Hum Mol Genet 1994; 3: 1633-1637.
6. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VK, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science 1991; 253: 1550-1553.
7. Rauscher FJ III, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms tumor locus zinc fingerprotein to the EGR-1 consensus sequence. Science 1990; 250: 1259-1262.
8. Bickmore WA, Oghene K, Little MH, Seawright A, van Heyningen V, Hastie ND. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor WT1 gene transcript. Science 1992; 257: 235-237.
9. Fraizer GC, Patmasiriwat P, Zhang X-H, Saunders GF. Expression of the tumor suppressor gene, WT1 in both human and murine bone marrow. Blood 1995; 86: 4704-4707.
10. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Fletcher RD, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, Haber DA. The Wilms' tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993; 4: 415-420.
11. Armstrong J, Pritchard-Jones K, Bickmore W, Hastie N, Bard B. The expression of the Wilms tumor gene, WT1, in the developing mammalian embryo. Mechanisms Devel 1992; 40: 85-97.
12. Miwa H, Beran M, Saunders CF. Expression of the Wilms' tumor gene (WT1) in human leukemia. Leukemia 1992; 6: 405-409.
13. Inoue K, Sugiyama H, Ogawa H, Nakagama M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
14. Fraizer GC, Wu Y-J, Hewitt SM. Maity T, Ton CCT, Huff V, Saunders GF. Transcriptional regulation of the human Wilms' tumor gene. J Biol Chem 1994; 269: 8892-8900.
15. Wu Y-J, Fraizer GC, Saunders GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. J Biol Chem 1995; 270: 5944-5949.
16. Orkin SH. GATA binding transcription factors in hematopoietic cells. Blood 1992; 80: 575-581.
17. Penvy L, Simon MC, Robertson E, Klein WH, Tsai S-F, Agati VD, Orkin SH, Costantini F. Erythroid differentiation in chimeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349: 257-260.
18. Simon MC, Penvy L, Wiles MV, Keller G, Costantini F, Orkin SH. Rescue of erythroid development in gene targeted GATA-1 mouse embryonic stem cells. Nat Genet 1992; 1: 92-98.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: report of the French-American-British Cooperative group. Ann Intern Med 1995; 103: 620-625.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
21. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729-2734.
22. Barch MJ (ed). The ACT Cytogenetic Laboratory Manual, 2nd edn. Raven Press: New York, 1991.
23. Mitelman F (ed). Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger, 1991, pp 1-54.
24. Liu P, Tarie SA, Hajira A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044.
25. Claxton DF, Lui P, Hsu HB, Marlton P, Hester J, Collins F. Deisseroth A, Rowley JD, Siciliano MJ. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994; 83: 1750-1756.
26. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler P, Miyoshi I. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970-977.
27. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9: 965-971.
28. Bitter MA, Le Beau MM, Larson RA, Rosner MC, Golomb HM, Rowley JD, Vardiman JW. A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophil associated with inv(16)(p13q22). Am J Clin Pathol 1984; 81: 733-744.
29. Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1984; 11: 310-313.
30. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic with abnormal eosinophil and inv(16) or t(16;16) has a favorable prognosis. Blood 1986; 68: 1242-1249.
31. Ohyashiki K, Ohyashiki JH, Kondo M, Ito H, Toyama K. Chromosome change at 16q22 in nonlymphocytic leukemia: clinical implication on leukemia patients with inv(16) versus del(16). Leukemia 1988; 2: 35-40.
32. Wotton D, Ghysdael J, Wang S, Speck NA, Owen MJ. Cooperative binding of Ets-1 and core binding factor to DNA. Mol Cell Biol 1994; 14: 840-850.
33. Zon LI, Orkin SH. Sequence of the human GATA-1 promoter. Nucleic Acids Res 1992, 20: 1812.
34. Ho IC, Bhat NK, Gottschalk LR, Lindsten T, Thomson CB, Papas TS, Leiden JM. Sequence specific binding of human Ets-1 to the T cell receptor α-gene enhancer. Science 1990; 250: 814-818.
35. Zhang D-E, Hetherington CJ, Chen H-M, Tenen G. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol Cell Biol 1994; 14: 373-381.
36. Pahl HL, Scheibe RJ, Zhang D-E, Chen H-M, Galson DL, Maki RA, Tenen DG. The proto-oncogene PU.1 regulates expression of the myeloid specific CD11b promoter. J Biol Chem 1993; 268: 5014-5020.